Deals In Depth: May 2011
Executive Summary
With a three-way tie, deals by Glenmark/Sanofi, Elan/Proteostasis, and Mundipharma/Allos were each valued at $50 million. Takeda expanded into Europe and emerging markets through its $14 billion buy of Nycomed, while PE firm Cinven scored big when it sold IVD investment Phadia to Thermo Fisher Scientific for $3.5 billion. Shanghai Pharma's $1.9 billion IPO on the Hong Kong Stock Exchange pushed biopharma financing in May up to $2.8 billion. Late VC financings in the device sector made up the majority of fundraising, which totaled $469 million.